Kejie Pharmaceutical-B (02171.HK) submitted the monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited as of August 31, 2024, on September 5, 2024. The report shows that the company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged at 200,000,000,000 shares and 571,539,915 shares for the month. In addition, according to the 2019 stock-based incentive plan, the potential number of new shares that may be issued is 3,766,992 shares. The company has confirmed that all securities issuance or sale of treasury shares has been authorized by the board of directors and complies with all relevant listing rules and legal requirements.

Kejie Pharmaceutical-B (02171.HK) submitted the monthly report on securities changes to the Hong Kong Exchanges and Clearing Limited as of August 31, 2024, on September 5, 2024. The report shows that the company's statutory/registered share capital and issued shares (excluding treasury shares) remained unchanged at 200,000,000,000 shares and 571,539,915 shares for the month. In addition, according to the 2019 stock-based incentive plan, the potential number of new shares that may be issued is 3,766,992 shares. The company has confirmed that all securities issuance or sale of treasury shares has been authorized by the board of directors and complies with all relevant listing rules and legal requirements.